Medical management of young, transplant-eligible patients
High priority
Your appointment may be a high priority if:
- You have recently been diagnosed with active or high-risk multiple myeloma. Your doctor will evaluate your specific clinical situation and will advise on the best approach for you. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia
Medium priority
Your appointment may be a medium priority if:
- You are receiving continuous first-line treatment. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia. Follow-up appointments to monitor treatment side effects will be conducted via telephone
- You are due to undergo autologous stem cell transplant. In these cases, your transplant may be delayed and your induction therapy extended for up to 6–8 cycles, and/or you may receive maintenance therapy with lenalidomide. If you are scheduled to undergo autologous stem cell transplant, you will be tested for COVID-19 before the transplant goes ahead
-
You are receiving maintenance therapy with lenalidomide. In these cases, your access to lenalidomide may be extended for up to 2 months and follow-up appointments will be conducted via telephone
- You need intravenous immunoglobulin replacement. In these cases, your doctor may alter your schedule so that you receive intravenous immunoglobulin less frequently
Low priority
Your appointment may be a low priority if:
- You are not receiving active treatment and you are in stable remission. Follow-up appointments will be conducted via telephone and treatment with bone modifying drugs may be delayed or reduced in frequency
Medical management of elderly, transplant non-eligible patients with newly-diagnosed multiple myeloma
High priority
Your appointment may be a high priority if:
- You have recently been diagnosed with active or high-risk multiple myeloma. Your doctor will evaluate your specific clinical situation and will advise on the best approach for you. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia
Medium priority
Your appointment may be a medium priority if:
-
You are receiving continuous treatment. If you have responded well to treatment with lenalidomide in combination with dexamethasone, your doctor may consider continuing your treatment with lenalidomide alone (or with a reduced dose of dexamethasone) to minimise the use of immunosuppressive drugs. Whenever possible, you will be treated with oral therapies but if injections are needed then your treatment may be given less frequently to minimise clinic visits. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia. Follow-up appointments to monitor treatment side effects will be conducted via telephone
Low priority
Your appointment may be a low priority if:
- You are in stable remission and are receiving continuous treatment, or you are in stable remission and are not receiving active treatment. Follow-up appointments will be conducted via telephone and treatment with bone modifying drugs may be delayed or reduced in frequency
Medical management of relapsed/refractory multiple myeloma
High priority
Your appointment may be a high priority if:
-
You have relapsed multiple myeloma that requires treatment, or you have refractory disease. Your doctor will evaluate your specific clinical situation and will advise on the best approach for you. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia
Medium priority
Your appointment may be a medium priority if:
- You are receiving continuous treatment for relapsed/refractory disease. If you have responded well to treatment with lenalidomide in combination with dexamethasone, your doctor may modify your treatment regimen to reduce the number of clinic visits required; for example, by using drugs that can be given once-weekly rather than twice-weekly or using oral therapies rather than injected ones. If you are being treated with daratumumab, you will be progressed to monthly administration as early as possible
Low priority
Your appointment may be a low priority if:
- You are in stable remission and are receiving continuous treatment for relapsed/refractory disease. Treatment with bone modifying drugs may be delayed or reduced in frequency
Medical management of smouldering multiple myeloma or monoclonal gammopathy of undetermined significance
Medium priority
Your appointment may be a medium priority if:
- You are undergoing surveillance for high-risk smouldering multiple myeloma. Your doctor will evaluate your specific clinical situation and will advise on the best approach for you. Scheduled appointments may be delayed or conducted via telephone and laboratory tests may be conducted at local clinics if possible
Low priority
Your appointment may be a low priority if:
- You have low-risk smouldering multiple myeloma or monoclonal gammopathy of undetermined significance. Scheduled appointments may be delayed or conducted via telephone and laboratory tests may be conducted at local clinics if possible